Kymera Therapeutics, Inc. (KYMR)
76.93
+2.98
(+4.03%)
USD |
NASDAQ |
Jun 09, 16:00
76.93
0.00 (0.00%)
After-Hours: 18:17
Kymera Therapeutics SG&A Expense (Quarterly) : 20.36M for March 31, 2026
SG&A Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
SG&A Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
SG&A Expense (Quarterly) Benchmarks
| Revolution Medicines, Inc. | 101.25M |
| Erasca, Inc. | 10.65M |
| Arrowhead Pharmaceuticals, Inc. | 41.74M |
| Sarepta Therapeutics, Inc. | 108.95M |
| Vir Biotechnology, Inc. | 23.34M |